Vistagen Therapeutics (VTGN) Competitors $2.43 -0.20 (-7.60%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$2.46 +0.02 (+1.03%) As of 09:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTGN vs. TSVT, ITOS, TERN, GLUE, LFCR, ALLO, AVIR, NGNE, AVTE, and SLRNShould you be buying Vistagen Therapeutics stock or one of its competitors? The main competitors of Vistagen Therapeutics include 2seventy bio (TSVT), iTeos Therapeutics (ITOS), Terns Pharmaceuticals (TERN), Monte Rosa Therapeutics (GLUE), Lifecore Biomedical (LFCR), Allogene Therapeutics (ALLO), Atea Pharmaceuticals (AVIR), Neurogene (NGNE), Aerovate Therapeutics (AVTE), and Acelyrin (SLRN). These companies are all part of the "pharmaceutical products" industry. Vistagen Therapeutics vs. 2seventy bio iTeos Therapeutics Terns Pharmaceuticals Monte Rosa Therapeutics Lifecore Biomedical Allogene Therapeutics Atea Pharmaceuticals Neurogene Aerovate Therapeutics Acelyrin 2seventy bio (NASDAQ:TSVT) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, community ranking, institutional ownership and valuation. Does the MarketBeat Community believe in TSVT or VTGN? Vistagen Therapeutics received 257 more outperform votes than 2seventy bio when rated by MarketBeat users. Likewise, 72.31% of users gave Vistagen Therapeutics an outperform vote while only 44.64% of users gave 2seventy bio an outperform vote. CompanyUnderperformOutperform2seventy bioOutperform Votes2544.64% Underperform Votes3155.36% Vistagen TherapeuticsOutperform Votes28272.31% Underperform Votes10827.69% Which has preferable earnings & valuation, TSVT or VTGN? Vistagen Therapeutics has lower revenue, but higher earnings than 2seventy bio. 2seventy bio is trading at a lower price-to-earnings ratio than Vistagen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio2seventy bio$48.37M5.50-$217.57M-$0.10-50.00Vistagen Therapeutics$698K100.48-$29.36M-$1.48-1.64 Do analysts recommend TSVT or VTGN? 2seventy bio currently has a consensus price target of $4.25, indicating a potential downside of 15.00%. Given 2seventy bio's higher possible upside, research analysts plainly believe 2seventy bio is more favorable than Vistagen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 2seventy bio 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80Vistagen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Does the media prefer TSVT or VTGN? In the previous week, 2seventy bio had 4 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 4 mentions for 2seventy bio and 0 mentions for Vistagen Therapeutics. 2seventy bio's average media sentiment score of 1.63 beat Vistagen Therapeutics' score of 0.00 indicating that 2seventy bio is being referred to more favorably in the media. Company Overall Sentiment 2seventy bio Very Positive Vistagen Therapeutics Neutral Which has more risk and volatility, TSVT or VTGN? 2seventy bio has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Is TSVT or VTGN more profitable? 2seventy bio has a net margin of -207.25% compared to Vistagen Therapeutics' net margin of -6,777.08%. Vistagen Therapeutics' return on equity of -48.12% beat 2seventy bio's return on equity.Company Net Margins Return on Equity Return on Assets 2seventy bio-207.25% -53.65% -23.67% Vistagen Therapeutics -6,777.08%-48.12%-43.80% Do insiders & institutionals believe in TSVT or VTGN? 93.9% of 2seventy bio shares are owned by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are owned by institutional investors. 7.2% of 2seventy bio shares are owned by company insiders. Comparatively, 1.3% of Vistagen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Summary2seventy bio beats Vistagen Therapeutics on 10 of the 18 factors compared between the two stocks. Get Vistagen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTGN vs. The Competition Export to ExcelMetricVistagen TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.14M$6.53B$5.38B$8.39BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-1.648.9226.7619.71Price / Sales100.48252.24389.71117.54Price / CashN/A65.8538.2534.62Price / Book0.866.466.784.50Net Income-$29.36M$143.98M$3.23B$248.18M7 Day Performance5.65%2.03%1.51%0.23%1 Month Performance18.54%4.11%10.03%12.39%1 Year Performance-42.96%-2.87%16.65%7.07% Vistagen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTGNVistagen Therapeutics1.214 of 5 stars$2.43-7.6%N/A-44.5%$70.14M$698,000.00-1.6440TSVT2seventy bio1.5487 of 5 stars$5.00+0.2%$4.25-15.0%N/A$266.15M$37.86M-2.69440Positive NewsITOSiTeos Therapeutics2.9712 of 5 stars$6.92+3.9%$25.50+268.5%-54.4%$264.86M$35M-2.2090Analyst RevisionHigh Trading VolumeTERNTerns Pharmaceuticals4.0973 of 5 stars$3.02-0.7%$18.38+508.4%-51.1%$263.76MN/A-2.5640News CoveragePositive NewsGap DownGLUEMonte Rosa Therapeutics2.1802 of 5 stars$4.27+4.4%$15.50+263.0%-6.6%$262.65M$75.62M-2.3390Positive NewsLFCRLifecore Biomedical1.2515 of 5 stars$6.98+0.1%$8.00+14.6%+8.2%$258.43M$130.31M-12.46690Analyst ForecastGap UpALLOAllogene Therapeutics3.4445 of 5 stars$1.17+0.9%$9.29+693.9%-58.7%$255.89M$22,000.00-0.75310Analyst RevisionAVIRAtea Pharmaceuticals2.4205 of 5 stars$2.96+8.8%$6.00+102.7%-22.2%$253.31MN/A-1.4370High Trading VolumeNGNENeurogene2.5223 of 5 stars$17.70+20.2%$47.20+166.7%-46.2%$252.44M$925,000.00-4.0790Analyst ForecastGap UpAVTEAerovate Therapeutics1.6212 of 5 stars$8.65-3.9%$78.75+810.4%-98.9%$250.72MN/A-2.8920Positive NewsGap UpHigh Trading VolumeSLRNAcelyrin3.5359 of 5 stars$2.48+5.1%$9.60+287.1%-47.4%$250.25MN/A-1.01135Positive News Related Companies and Tools Related Companies TSVT Alternatives ITOS Alternatives TERN Alternatives GLUE Alternatives LFCR Alternatives ALLO Alternatives AVIR Alternatives NGNE Alternatives AVTE Alternatives SLRN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTGN) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vistagen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vistagen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VTGN Stock Free VTGN Stock Alerts